XLONVRCI
Market cap7mUSD
Dec 24, Last price
2.38GBP
1D
0.00%
1Q
-64.74%
IPO
-94.83%
Name
Verici Dx Plc
Chart & Performance
P/E
—
P/S
714.18
EPS
—
Div Yield, %
0.00%
Shrs. gr., 5y
—
Rev. gr., 5y
%
Revenues
1m
Net income
-9m
L-23.11%
CFO
-7m
L-28.88%
Earnings
May 28, 2025
Profile
Verici Dx plc, an immuno-diagnostics development company, focuses on the kidney transplantation market. The company develops prognostic and diagnostic tests for kidney transplant patients. Its in-development tests include Clarava, a pre-transplant prognosis test for the risk of early acute rejection; Tuteva, a post-transplant test that focuses on acute cellular rejection; and Protega, a liquid biopsy that aims to predict the risk of fibrosis and long-term graft failure. The company was incorporated in 2020 and is based in Penarth, the United Kingdom.
Valuation
Title USD in thousands, except ratios and share amounts | FY | FY | FY | FY |
|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | |
| Income | ||||
Revenues | 1,013 | |||
Cost of revenue | 8,598 | 15,329 | 5,372 | |
Unusual Expense (Income) | ||||
NOPBT | (7,585) | (15,329) | (5,372) | |
NOPBT Margin | ||||
Operating Taxes | (48) | (740) | ||
Tax Rate | ||||
NOPAT | (7,585) | (15,281) | (4,632) | |
Net income | (8,734) -23.11% | (11,359) 36.37% | (8,330) 17.28% | |
Dividends | ||||
Dividend yield | ||||
Proceeds from repurchase of equity | 13,070 | |||
BB yield | -63.50% | |||
| Debt | ||||
Debt current | 163 | 156 | ||
Long-term debt | 917 | 312 | ||
Deferred revenue | ||||
Other long-term liabilities | 544 | |||
Net debt | (1,565) | (9,337) | (10,340) | |
| Cash flow | ||||
Cash from operating activities | (7,160) | (10,068) | (6,336) | |
CAPEX | (23) | (1,308) | (966) | |
Cash from investing activities | (231) | (1,308) | (966) | |
Cash from financing activities | (27) | 12,674 | (74) | |
FCF | (6,938) | (16,505) | (4,953) | |
| Balance | ||||
Cash | 2,645 | 9,805 | 10,340 | |
Long term investments | ||||
Excess cash | 2,594 | 9,805 | 10,340 | |
Stockholders' equity | (32,987) | (21,437) | (8,369) | |
Invested Capital | 37,085 | 33,802 | 20,354 | |
ROIC | ||||
ROCE | ||||
| EV | ||||
Common stock shares outstanding | 170,319 | 164,668 | 141,748 | |
Price | 0.10 -22.00% | 0.13 -76.42% | 0.53 -9.40% | |
Market cap | 16,606 -19.32% | 20,583 -72.60% | 75,126 48.07% | |
EV | 15,041 | 11,246 | 64,787 | |
EBITDA | (6,756) | (14,689) | (4,934) | |
EV/EBITDA | ||||
Interest | 29 | 5 | ||
Interest/NOPBT | ||||